Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro

Clinical Cancer Research

Volumn 18, Issue 19, 2012, Pages 5364-5373

  Schenk, Erin L ^a   Koh, Brian D ^a   Flatten, Karen S ^a   Peterson, Kevin L ^a   Parry, David ^c,e   Hess, Allan D ^d   Smith, B Douglas ^d   Karp, Judith E ^d   Karnitz, Larry M ^a,b   Kaufmann, Scott H ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e Portola Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 1; CYTARABINE; ENZYME INHIBITOR; GEMCITABINE; SCH 900776; TANESPIMYCIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DIVISION; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTARABINE; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84866924927     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0961     Document Type: Article

References (50)

1. Tallman MS, Gilliland DG, Rowe JM. Drug therapy of acute myeloid leukemia. Blood 2005;106:1154-63. (Pubitemid 41130866)
2. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011;29:487-94.
3. Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009;31:2349-70.
4. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001;21:4129-39. (Pubitemid 32565295)
5. Loegering D, Arlander SAH, Hackbarth J, Vroman B, Lieberman HB, Karnitz LM, et al. Rad9 protects cells from topoisomerase poison-induced cell death. J Biol Chem 2004;279:18641-7. (Pubitemid 38623286)
6. Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SAH, Dai NT, et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 2005;106:318-27. (Pubitemid 40967208)
7. Cho SH, Toouli CD, Fujii GH, Crain C, Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 2005;4:131-9. (Pubitemid 41038942)
8. Shi Z, Azuma A, Sampath D, Li YX, Huang P, Plunkett W. S-phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res 2001;61:1065-72. (Pubitemid 32174426)
9. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 2003;300:1542-8. (Pubitemid 36682880)
10. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 2008;9:616-27. (Pubitemid 352032926)
11. Zegerman P, Diffley JF. DNA replication as a target of the DNA damage checkpoint. DNA Repair (Amst) 2009;8:1077-88.
12. Paulsen RD, Cimprich KA. The ATR pathway: fine-tuning the fork. DNA Repair (Amst) 2007;6:953-66. (Pubitemid 46880476)
13. Wagner JM, Kaufmann SH. Prospects for the use of ATR inhibitors to treat cancer. Pharmaceuticals 2010;3:1311-34.
14. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010;16:376-83.
15. Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ, et al. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 2005;68:1636-44. (Pubitemid 41654347)
16. Ashwell S, Janetka JW, Zabludoff S. Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opin Investig Drugs 2008;17:1331-40.
17. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011;17:88-96.
18. Arlander SJH, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 2003;278:52572-7. (Pubitemid 38035854)
19. Arlander SJ, Felts SJ, Wagner JM, Stensgard B, Toft DO, Karnitz LM. Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones. J Biol Chem 2006;281:2989-98. (Pubitemid 43845766)
20. Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, et al. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica 2011;96:1619-26.
21. Wang S, Wang Z, Grant S. Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms. Mol Pharmacol 2003;63:232-42. (Pubitemid 36043827)
22. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 2006;107:2517-24. (Pubitemid 43345576)
23. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000;60:2108-12. (Pubitemid 30225168)
24. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, et al. The Chk1 protein kinase and the Cdc25C regulator pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000;275:5600-5. (Pubitemid 30115197)
25. Ruegg UT, Burgess GM. Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci 1989;10:218-20. (Pubitemid 19146392)
26. Yu Q, La Rose J, Zhang H, Takemura H, Kohn KW, Pommier Y. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res 2002;62:5743-8. (Pubitemid 35204730)
27. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002;21:1727-38. (Pubitemid 34259036)
28. Janetka JW, Almeida L, Ashwell S, Brassil PJ, Daly K, Deng C, et al. Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors. Bioorg Med Chem Lett 2008;18:4242-8.
29. Graham FL, Whitmore GF. Studies in mouse L-cells on the incorporation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphatase. Cancer Res 1970;30:2636-44.
30. Major PP, Egan EM, Beardsley GP, Minden MD, Kufe DW. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc Natl Acad Sci U S A 1981;78:3235-9. (Pubitemid 11032022)
31. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 2000;287:1824-7.
32. Guzi TJ, Paruch K, Dwyer MP, Labroli M, Shanahan F, Davis N, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther 2011;10:591-602.
33. Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng Y-C, Rowinsky EK. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood 1997;89:2098-104. (Pubitemid 27132126)
34. Eaves C, Lambie K. Atlas of human hematopoietic colonies. Vancouver: StemCell Technologies Inc.; 1995.
35. Mesa RA, Tefferi A, Gray LA, Reeder T, Schroeder G, Kaufmann SH. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia 2003;17:849-55. (Pubitemid 36626310)
36. Kaufmann SH. Reutilization of immunoblots after chemiluminescent detection. Anal Biochem 2001;296:283-6. (Pubitemid 32868511)
37. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000;14:1448-59. (Pubitemid 30421838)
38. Zhang Y-W, Otterness DM, Chiang GG, Xie W, Liu Y-C, Mercurio F, et al. Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell 2005;19:607-18. (Pubitemid 41219437)
39. Leung-Pineda V, Ryan CE, Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 2006;26:7529-38. (Pubitemid 44547703)
40. Amarante-Mendes GP, Kim CN, Liu L, Huang Y, Perkins C, Green DR, et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3. Blood 1998;91:1700-5. (Pubitemid 28110335)
41. Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown TL. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 2003;8:345-52. (Pubitemid 36935206)
42. Wagner JM, Karnitz LM. Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival. Mol Pharmacol 2009;76:208-14.
43. Montano R, Chung I, Garner KM, Parry D, Eastman A. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther 2012;11:427-38.
44. Berenbaum MC. What is synergy? Pharmacol Rev 1989;41:93-141. (Pubitemid 20019599)
45. Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, et al. Phase I and pharmacological study of infusional topotecan and carboplatin in relapsed and refractory leukemia. Clin Cancer Res 2005;11:6641-9. (Pubitemid 41339005)
46. Kaneko YS, Watanabe N, Morisaki H, Akita H, Fujimoto A, Tominaga K, et al. Cell-cycle-dependent and ATM-independent expression of human Chk1 kinase. Oncogene 1999;18:3673-81. (Pubitemid 29338500)
47. Agner J, Falck J, Lukas J, Bartek J. Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway. Exp Cell Res 2005;302:162-9. (Pubitemid 39550459)
48. Ho CC, Siu WY, Chow JP, Lau A, Arooz T, Tong HY, et al. The relative contribution of CHK1 and CHK2 to adriamycin-induced checkpoint. Exp Cell Res 2005;304:1-15. (Pubitemid 40222072)
49. Sampath D, Shi Z, Plunkett W. Inhibition of cyclin dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine. Mol Pharmacol 2002;62:680-8. (Pubitemid 36329387)
50. Rodriguez-Bravo V, Guaita-Esteruelas S, Salvador N, Bachs O, Agell N. Different S/M checkpoint responses of tumor and non tumor cell lines to DNA replication inhibition. Cancer Res 2007;67:11648-56.